Phase 3 Study of MRTX849 (Adagrasib) vs. Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) [42]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.